MX2022014440A - Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. - Google Patents
Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.Info
- Publication number
- MX2022014440A MX2022014440A MX2022014440A MX2022014440A MX2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A
- Authority
- MX
- Mexico
- Prior art keywords
- administering
- inhibitor
- methods
- eosinophilic esophagitis
- treating eosinophilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029085P | 2020-05-22 | 2020-05-22 | |
| US202063066705P | 2020-08-17 | 2020-08-17 | |
| US202063071264P | 2020-08-27 | 2020-08-27 | |
| US202063088147P | 2020-10-06 | 2020-10-06 | |
| US202063121088P | 2020-12-03 | 2020-12-03 | |
| US202163144939P | 2021-02-02 | 2021-02-02 | |
| EP21315068 | 2021-04-21 | ||
| PCT/US2021/033693 WO2021237110A1 (en) | 2020-05-22 | 2021-05-21 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014440A true MX2022014440A (es) | 2023-02-27 |
Family
ID=76444669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014440A MX2022014440A (es) | 2020-05-22 | 2021-05-21 | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250154267A2 (https=) |
| EP (1) | EP4153300A1 (https=) |
| JP (1) | JP2023527775A (https=) |
| KR (1) | KR20230015965A (https=) |
| CN (1) | CN115768516A (https=) |
| AU (1) | AU2021277398A1 (https=) |
| BR (1) | BR112022022235A2 (https=) |
| CA (1) | CA3174431A1 (https=) |
| IL (1) | IL298257A (https=) |
| MX (1) | MX2022014440A (https=) |
| WO (1) | WO2021237110A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| AU2023259352A1 (en) * | 2022-04-26 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Transcriptome analysis for treating inflammation |
| WO2024011251A1 (en) * | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| CN121001741A (zh) | 2023-03-27 | 2025-11-21 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法 |
| WO2025221247A1 (en) * | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102460040B1 (ko) * | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI728172B (zh) * | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| US11053309B2 (en) * | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| JP2021514513A (ja) * | 2018-02-21 | 2021-06-10 | アデア ファーマシューティカルズ，ユーエス，エル．ピー． | 好酸球性食道炎を管理する方法 |
| CN112261954B (zh) * | 2018-06-14 | 2025-06-24 | 味之素株式会社 | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-05-21 JP JP2022571133A patent/JP2023527775A/ja active Pending
- 2021-05-21 CA CA3174431A patent/CA3174431A1/en active Pending
- 2021-05-21 CN CN202180036330.4A patent/CN115768516A/zh active Pending
- 2021-05-21 EP EP21732754.3A patent/EP4153300A1/en active Pending
- 2021-05-21 BR BR112022022235A patent/BR112022022235A2/pt unknown
- 2021-05-21 AU AU2021277398A patent/AU2021277398A1/en active Pending
- 2021-05-21 MX MX2022014440A patent/MX2022014440A/es unknown
- 2021-05-21 US US17/327,504 patent/US20250154267A2/en active Pending
- 2021-05-21 IL IL298257A patent/IL298257A/en unknown
- 2021-05-21 WO PCT/US2021/033693 patent/WO2021237110A1/en not_active Ceased
- 2021-05-21 KR KR1020227045054A patent/KR20230015965A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023527775A (ja) | 2023-06-30 |
| US20250154267A2 (en) | 2025-05-15 |
| US20210363264A1 (en) | 2021-11-25 |
| CN115768516A (zh) | 2023-03-07 |
| CA3174431A1 (en) | 2021-11-25 |
| AU2021277398A1 (en) | 2023-02-02 |
| KR20230015965A (ko) | 2023-01-31 |
| BR112022022235A2 (pt) | 2023-03-28 |
| EP4153300A1 (en) | 2023-03-29 |
| WO2021237110A1 (en) | 2021-11-25 |
| IL298257A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014440A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| CL2025002241A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| CY1124095T1 (el) | Μεθοδοι για την ενισχυση της ειδικης ανοσοθεραπειας εναντι αλλεργιογονου με χορηγηση αναστολεα του ιl-4r | |
| MX2021005008A (es) | Moduladores de celulas t reguladoras multivalentes. | |
| CO2022013525A2 (es) | Anticuerpos contra sars-cov-2 y métodos para usarlos | |
| CY1122909T1 (el) | Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r | |
| MX387530B (es) | Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña. | |
| CO2021007053A2 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| MX2022001030A (es) | Metodos para tratar alergia y mejorar la inmunoterapia especifica de alergenos mediante la administracion de un antagonista de il-4r. | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
| MX2018013172A (es) | Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13. | |
| MX2022011730A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| EA201590720A8 (ru) | АНТИ-Flt-1-АНТИТЕЛА В ЛЕЧЕНИИ МЫШЕЧНОЙ ДИСТРОФИИ ДЮШЕНА | |
| PH12022550246A1 (en) | A dosing regimen for an ido inhibitor | |
| MX2021006980A (es) | Anticuerpos anti-il-27 y usos de estos. | |
| MX2020009879A (es) | Anticuerpos anti-il-27 y sus usos. | |
| MX2025011152A (es) | Metodos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc) mediante la administracion de un antagonista de il-4r | |
| CO2024001388A2 (es) | Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2 | |
| MX2024002072A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| MX2022003719A (es) | Anticuerpos anti-il-27 y sus usos. | |
| MX2025011114A (es) | Metodos para el tratamiento de la gastroenteritis eosinofilica mediante la administracion de un antagonista de il-4r | |
| MX2022015677A (es) | Metodos para tratar la alergia usando anticuerpos anti-bet v 1. |